Trial reportBMC ophthalmology2025
Longitudinal safety and efficacy of dual treatment with orthokeratology lenses and 0.01% atropine eye drops: a focus on epithelial changes and tear film stability.
Trial report in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Compliance with orthokeratology lens wear: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Current Evidence on Options and Efficacy of Combination Therapy for Myopia Control-A Narrative Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The longitudinal evaluation of the dual treatment protocol combining orthokeratology (Ortho-K) lenses and 0.01% atropine eye drops focused on assessing tear film stability, corneal epithelial alterations, and visual function in pediatric myopia control. This prospective, randomized study enrolled 100 participants aged 8 to - 18 years, categorized into Group A (Ortho-K + 0.01% atropine) and Group B (Ortho-K monotherapy). The subjects were followed for 12 months, with assessments at 1, 3, 6, and 12 months. The key parameters analyzed included axial length progression, spherical equivalent refraction, best-corrected visual acuity (BCVA), corneal topography, corneal epithelial thickness, corneal endothelial cell density, intraocular pressure (IOP), tear break-up time (TBUT), Schirmer's test results, and ocular surface integrity determined via fluorescein and lissamine green staining. Compared with Group B (Δ0.5 ± 0.07 mm, p < 0.05), Group A exhibited superior myopia control, with a significant reduction in axial elongation (Δ0.3 ± 0.05 mm, p = 0.04). BCVA improved more in Group A (-0.1 ± 0.04 LogMAR, p = 0.03) than in Group B (-0.15 ± 0.04 LogMAR, p < 0.05). However, tear film stability decreased in Group A, as evidenced by a greater reduction in TBUT (Δ1.5 ± 0.3 s, p = 0.04) than in Group B (Δ0.7 ± 0.2 s, p = 0.05). Corneal epithelial thinning was more pronounced in Group A (Δ2.5 ± 0.5 μm, p = 0.05) than in Group B (Δ1.0 ± 0.3 μm, p = 0.07). No significant differences in Schirmer's test, endothelial cell density, or IOP were noted between the groups. Patient adherence was greater in Group A than in Group B (93% vs. 91%), and both groups reported high patient satisfaction scores. These findings suggested that dual therapy enhances myopia control while maintaining corneal and ocular surface integrity, although tear film stability and epithelial health require careful long-term monitoring. Further longitudinal studies with larger cohorts are necessary to confirm the long-term safety and efficacy of this combined approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.